Oxford BioTherapeutics Ltd has appointed C. Glenn Begley as a senior clinical advisor and non-executive director as it prepares to advance its antibody-based drugs into clinical development. Dr Begley was previously vice president and global head of haematology and oncology research at Amgen Inc. He is certified in Australia as a medical oncologist and haematologist and holds a PhD in cellular and molecular biology.
Oxford BioTherapeutics announced the appointment on 11 January 2012.
Copyright 2012 Evernow Publishing Ltd